Similar articles

• Rotavirus vaccines for children in developing countries: understanding the science, maximizing the impact, and sustaining the effort.

  Neuzil KM, Parashar UD, Steele AD. Neuzil KM, et al. Vaccine. 2012 Apr 27;30 Suppl 1:A1-2. doi: 10.1016/j.vaccine.2011.10.108. Vaccine. 2012. PMID: 22520117 No abstract available.
• Rotavirus vaccines: targeting the developing world.

  Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Glass RI, et al. J Infect Dis. 2005 Sep 1;192 Suppl 1:S160-6. doi: 10.1086/431504. J Infect Dis. 2005. PMID: 16088799
• Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization.

  Christie CD, Duncan ND, Thame KA, Onorato MT, Smith HD, Malcolm LG, Itzler RF, Dinubile MJ, Heaton PM. Christie CD, et al. Pediatrics. 2010 Dec;126(6):e1499-506. doi: 10.1542/peds.2010-1240. Epub 2010 Nov 29. Pediatrics. 2010. PMID: 21115586 Clinical Trial.
• Rotavirus in Asia: the value of surveillance for informing decisions about the introduction of new vaccines.

  Bresee JS, Hummelman E, Nelson EA, Glass RI. Bresee JS, et al. J Infect Dis. 2005 Sep 1;192 Suppl 1:S1-5. doi: 10.1086/431515. J Infect Dis. 2005. PMID: 16088790 Review. No abstract available.
• A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception.

  Kapikian AZ, Simonsen L, Vesikari T, Hoshino Y, Morens DM, Chanock RM, La Montagne JR, Murphy BR. Kapikian AZ, et al. J Infect Dis. 2005 Sep 1;192 Suppl 1:S22-9. doi: 10.1086/431510. J Infect Dis. 2005. PMID: 16088801 Review.